Dr. Scarpato on NMIBC: “We need more biomarkers”
“In non–muscle-invasive bladder cancer, we need more biomarkers, something that can hopefully reduce the frequency of invasive procedures for these patients,” says Kristen Scarpato, MD, MPH.
In this video, Kristen Scarpato, MD, MPH, discusses what is being done to improve the treatment options for patients with non–muscle-invasive bladder cancer, including what she does in her own practice. These ideas were focused on in a case-based discussion on intermediate-risk non–muscle-invasive bladder cancer that took place during the 2021 Society of Urologic Oncology Annual Meeting. Scarpato is an associate professor, residency program director, and vice chair of education in the department of urology at the Vanderbilt University Medical Center in Nashville, Tennessee.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Mistrust of medical research may discourage genetic testing in prostate cancer
November 20th 2023According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.
